Home / Available Projects / Therapeutic antibody against Frizzled 4

Therapeutic antibody against Frizzled 4
Online Inquiry

Drug Name	GPCR-targeted Project 018
Description	Frizzled 4 (FZD4) belongs to the frizzled receptors family. It is a receptor for Wnt proteins, which can activate both Wnt/β-catenin canonical and Wnt/Ca2+ non canonical pathways. FZD4 plays an important role in retinal vascularization by binding Norrin ligand, a Wnt-unrelated growth factor, and activating the β-catenin signaling pathway. In addition, dysregulation of FZD4 expression has been reported in different type of cancers. A monoclonal antibody specifically binding to FZD4 with high affinity is being developed. Preclinical development for familial exudative vitreoretinopathy (FEVR) and cancers is ongoing.
Target	Frizzled 4 (FZD4)
Drug Modality	Monoclonal antibody
Indication	Familial exudative vitreoretinopathy; Cancers
Product Category	Biologic
Mechanism of Action	Frizzled 4 modulators
Status	Preclinical
Patent	Granted

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry